HLB (028300) Q2 2025 earnings summary

Executive summary

• Operates in three main segments: healthcare (diagnostics, medical devices), bio-pharmaceuticals (oncology drug development), and shipbuilding (specialty vessels, lifeboats, pipes).

• Recent focus on expanding bio and healthcare, with shipbuilding spun off in 2023.

• Major subsidiaries include Elevar Therapeutics and Immunomic Therapeutics, both active in global clinical trials and licensing.

Financial highlights

• 2025 H1 consolidated revenue: KRW 33.4 billion, down from KRW 68.1 billion in 2024.

• Operating loss for 2025 H1: KRW -51.8 billion; net loss: KRW -129.7 billion.

• Cash and equivalents at 2025 H1: KRW 53.0 billion, down from KRW 93.0 billion at 2024 year-end.

• Equity at 2025 H1: KRW 513.8 billion; total assets: KRW 745.3 billion.

Outlook and guidance

• Focus on commercialization of oncology drugs (Rivoceranib, Lirafugratinib) with pending FDA/EMA submissions.

• Plans to expand global healthcare and diagnostics sales, with new product launches and B2C strategies.

• Continued investment in R&D and pipeline expansion, especially in bio and immunotherapy.